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 Abstract 
  Background/Aims:   Psychotropics and antiepileptics (AE) are medications commonly used 
among the aged with cognitive decline or dementia, although they may precipitate further 
cognitive decline. Our aim was to analyze the relationships between the use of (i) psychotropics 
(i.e. benzodiazepines or related drugs, BZD, antipsychotics, AP, or antidepressants, AD), opioids 
(Op), anticholinergics (ACh) or AEs or the concomitant use of two of these drugs, and (ii) the risk 
of precipitous cognitive decline in an older (  6  65 years) cognitively disabled population.   Meth-
ods:  A longitudinal population-based study of general aged community-dwelling patients was 
executed in two phases (1990–1991 and 1998–1999) in Lieto, Finland. Fifty-two individuals cog-
nitively disabled (MMSE score 0–23) at the 1990–1991 baseline form this study’s sample. Cogni-
tive abilities were assessed in each phase with the Mini-Mental State Examination (MMSE) and 
medication utilization data were collected in both phases. The mean follow-up time was 7.6 
years. Multivariate models were used to analyze the change in MMSE total score between med-
ication users and non-users.   Results:   BZD or any psychotropic use was associated with greater 
cognitive decline in elders aged  6 75 years compared to non-users (change in MMSE sum score: 
–8.6   8   7.0 vs. –3.3   8   5.6 and –5.9   8   7.0 vs. –2.7   8   6.4, respectively). A greater decline was also 
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associated specifically with the concomitant use of BZD and AP (–16 vs. –1.4  8  7.8); as were BZD 
and any drug with CNS effects (–9.6   8   9.9 vs. –1.3   8   7.2) compared to non-users. The concom-
itant use of BZD and AD (–10.7   8   4.7 vs. –3.2   8   5.6) or ACh (–15.0   8   8.5 vs. –3.3   8   5.6) or any 
drug with CNS effects (–13.3   8   6.5 vs. –3.3   8   5.6) was associated with cognitive decline in pa-
tients   6  75 years compared to non-users of any drug with CNS effects.   Conclusion:   The use of 
a BZD or any psychotropic medication may be an independent risk factor for cognitive decline 
in the cognitively disabled aged, and patients co-prescribed psychotropic medications had 
greater cognitive decline. Studies with larger sample sizes and studies on possible pathophysi-
ologic mechanisms are needed.    Copyright © 2012 S. Karger AG, Basel 
 Introduction 
  Psychotropics   [1–4]   and antiepileptic medications   [5–7]   are commonly used to treat the 
behavioral and psychological symptoms of dementia   [8]  . A concern, however, has arisen as 
to whether these medications may lead to a precipitous cognitive deterioration among pa-
tients with pre-existing cognitive decline or dementing diseases.
  Conventional antipsychotics (AP) can cause anticholinergic and extrapyramidal adverse 
effects in the aged   [9]  . A randomized, placebo-controlled trial failed to show a positive ben-
efit/risk ratio for the use of APs among home-dwelling elders with Alzheimer’s disease   [10]  . 
Some longitudinal epidemiologic studies   [11, 12]   and randomized controlled trials   [13, 14]   
have shown that AP use is related to a precipitous cognitive decline among patients with de-
menting diseases. This relationship has not been reported in other longitudinal epidemio-
logic studies   [15–18]   or short-term treatment studies   [10, 19–21]  .
  There is some evidence of an association between the use of medications other than APs 
which have CNS effects and cognitive decline. Benzodiazepines or related drugs (BZD) may 
worsen cognition in patients with Alzheimer’s disease, especially when combined with APs 
 [12] . Antidepressants (AD) with anticholinergic properties (especially tricyclic ADs) are cog-
nitively toxic to aged patients while patients may tolerate non-anticholinergic selective sero-
tonin re-uptake inhibitors (SSRIs)   [22]  . The adverse effects of anticholinergic medications 
(AChs) have been extensively documented in both non-demented and demented populations 
  [23, 24]  . Community-dwelling individuals using AChs are five times more likely to be clas-
sified as cognitively impaired compared to non-users; however, no excess risk of developing 
dementia was detected   [25]  .
  Due to a lack of evidence and contradictory trial results  [26] , a systematic review did not 
recommend routine use of antiepileptics (AE) in treating the behavioral and psychological 
symptoms of dementia   [8]  . Our literature search did not identify any studies on the use of 
opioids (Op) and modified risk of cognitive deterioration in cognitively disabled patients, nor 
have Op therapies for chronic pain among patients with dementia been studied   [27]  .
  The analyses in the studies above, with the exception of one study  [12] , only consider the 
use of a single drug type. Consequently, the adverse effects of concomitant use of drugs with 
CNS effects on patients with pre-existing cognitive decline have not been explored. How-
ever, concomitant use of several kinds of drugs with CNS effects is common in pharmaco-
therapy for older patients   [28]  , especially among those with dementia   [29]  . In a longitudinal 
study conducted in cognitively intact aged, the concomitant use of Ops and BZDs or Ops and 
any type of CNS medication was associated with the cognitive decline compared to non-
users of these medications   [30]  . It can be hypothesized that the concomitant use of psycho-
tropics or other drugs with CNS effects may have stronger negative effects on cognitive func-
tion than the use of a single drug with such effects.59
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    The aim of the present study was to describe and analyze the relationships between the 
use of a psychotropic (i.e. BZD, AP or AD), opioid, anticholinergic or antiepileptic drug or 
the concomitant use of two of these drugs, and the risk of precipitous cognitive decline in a 
population aged   6  65 years with deteriorated cognitive functioning at baseline.
  M e t h o d s  
  Participants and Data Collection 
  This study was part of a longitudinal population-based study performed in the munici-
pality of Lieto, South-Western Finland  [31, 32] . The first phase of the Lieto study was carried 
out between October 1, 1990 and December 31, 1991, and the second phase between March 
1, 1998 and September 31, 1999.
    The population of the first phase consisted of residents who were born in 1926 or earlier 
(n = 1,283). Of these, 1,196 (93%, 488 men and 708 women) participated. The population of 
the second phase consisted of residents born in 1933 or earlier (n = 1,533) of whom 1,260 
(82%) participated. The validated Finnish version of the Mini-Mental State Examination 
(MMSE)   [33]   was administered to all participants. Its scale consists of 23 items, and the sum 
score ranges from 0 to 30, with higher scores indicating better cognitive performance.
    The population for the present longitudinal study was formed from those (i) who par-
ticipated in the first phase and had a total score of 0–23 on the MMSE   [34]  , indicating dete-
riorated cognitive functioning, and (ii) who were alive and participated in the second phase. 
The realized sample of the study population consisted of 52 residents (17 men and 35 wom-
en); the mean follow-up time was 7.6   8   0.5 years (range: 6.6–8.7 years).
  During both phases, proxies (relatives or caregivers) of the participants were interviewed 
for information on the participants’ socioeconomic background, physical and psychosocial 
factors and functional abilities, their use of drugs and health behavior(s). Participants were 
clinically examined by a health center physician belonging to the research team (R.I. or 
M.L.), and clinical tests were performed. Medical records in the Härkätie Health Centre, 
Lieto, were used to record previously diagnosed diseases. Similar processes were performed 
in both phases. Cognitive abilities were measured by a trained nurse using the MMSE   [34]   
in both study phases. Information about medication use was collected in the proxy inter-
views. Subjects and their proxies had been requested to bring all of their prescription forms 
and drugs with them so that actual medication use could be confirmed. All regularly or ir-
regularly taken prescription drugs and non-prescribed drugs (e.g. vitamins) taken during the 
seven days prior to the interview were recorded.
    Drugs were defined by using the Anatomical Therapeutic Chemical (ATC) Classifica-
tion   [35]  . The groups of drugs defined as having a CNS effect and therefore included in the 
analyses were: Ops (ATC codes N01AH, N02A, N02BE51, R05DA, R05FA), AChs (ATC
codes N04A, N05AA01, N05AA02, N05AB01, N05AB02, N05AB03, N05AB04, N05AC01, 
N05AC02, N05AF01, N05AF03, N05AF05, N05BB01, N06AA04, N06AA06, N06AA09, 
N06AA12, 102AG, A03AA, A03AB, A03AX03, A03B, A03CA, A03CB31, A03DA, A03FA01, 
A04AD01, A04AD12, C01BA01, C01BA03, C01BA51, C01BA71, R03BB, M03B, G04BD, 
S01FA, R01BA01, R01BA51, R06AB01, R06AE03, R06AE53), AEs (ATC code N03A), BZDs 
(ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, 
N02BA71), APs (ATC codes N05A, N06CA01), and ADs (ATC code N06A, N06CA).
  In both study phases, informed consent was obtained from every participant’s relative 
or formal caregiver. Plans for both the first and second Lieto studies were approved by the 
Joint Ethics Committee of the University of Turku and Turku University Central Hospi-
tal.60
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  Statistical  Analyses 
 Statistical analyses were performed on the total population and separately by gender and 
age group (younger age group: 65–74 years; older age group:   6  75 years). Participants using 
a CNS medication at the beginning of the follow-up were compared (i) with participants who 
did not use any of these medications at baseline and (ii) with participants not using that spe-
cific medication. Participants using a combination of two or more of the CNS medications 
were compared with participants using none of the individual CNS medications or their 
combinations.
     2   and Fisher’s exact tests were used to test differences between genders and age groups, 
and between medication users and control groups at baseline and during the follow-up ex-
amination. The statistical significance of differences in the use of medications between base-
line and follow-up examination was analyzed with McNemar’s test for every group of medi-
cations. The significance of changes in MMSE total scores during the follow-up in the total 
population and in all subgroups was tested with the Wilcoxon signed rank test. Differences 
between mean MMSE total scores and the changes of mean MMSE total scores between the 
groups were tested with the Mann-Whitney U test. Associations between the use of a spe-
cific group of CNS medications or the use of a combination of CNS medications and the risk 
of cognitive decline were analyzed by the Mann-Whitney U test. Significance of differences 
in cognitive functioning changes during the follow-up between the users of a certain group 
of CNS medications or the users of a combination of CNS medications and the correspond-
ing control group of non-users was tested with the Mann-Whitney U test. As these are non-
parametric tests, our analyses conservatively estimate realized p values.
    After these analyses, adjusted analyses using analysis of covariance were performed for 
those groups in which the associations between the use of a certain CNS medication or the 
concomitant use of certain CNS medications and the risk for cognitive decline were either 
significant (p  !  0.05) or tending toward significant (0.05  !  p  !  0.10) in the bivariate analyses. 
Associations between probable confounding variables (age, sex, education, hypertension, 
atrial fibrillation or flutter, diabetes mellitus, congestive heart disease and smoking at base-
line) and the decline in MMSE total scores were analyzed in the total population. From these 
variables, higher age (p = 0.0007) was associated with a statistically significant decline in 
MMSE total scores. Thus, only this variable was controlled as a confounding variable in the 
analyses of covariance.
  R e s u l t s  
 Background  Data 
  Altogether 52 individuals participated in both phases of the study. Their MMSE total 
scores at baseline ranged from 0 to 23 (indicating deteriorated cognitive functioning). Fifteen 
(29%) were men and 37 (71%) women. The majority (n = 30; 58%) were   6  75 years at the be-
ginning of the follow-up, and 22 (42%) were 65–74 years old. The mean age   8   SD was 75.9 
  8   7.2 years (range: 64–92). 
    Altogether 15 participants (29%) lived at home with other people, 33 (63%) lived alone, 
and 4 (8%) were institutionalized. Thirty-nine (76%) were able to walk independently, 10 
(20%) with an assistive device, and 2 (4%) with the help of another person. The mean number 
  8   SD of prescribed medications used regularly was 2.8   8   2.4, and that of drugs used ir-
regularly (as needed) was 0.8   8   1.1.61
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    Use of Drugs at Baseline and during Follow-Up Examination 
 At baseline, BZDs and AChs were used by approximately every fifth participant ( table 1 ). 
APs, ADs and Ops were used by every tenth participant. Half of the participants used at least 
one drug with effects on the CNS. No differences in the use of these drugs were found be-
tween men and women. Opioid use was more common among the older age group (20%) 
than among the younger one (0%) (p = 0.0328). Similarly, the use of at least one drug with 
effects on the CNS was more common among the older age group (63%) than among the 
younger one (23%) (p = 0.0051). The use of AD tended to be more common among the older 
age group than among the younger one but the difference did not achieve statistical signifi-
cance. The use of these drugs did not change significantly from baseline during the follow-
up. Ten to seventeen percent of the participants received concomitantly at least two drugs 
with effects on the CNS (  table 2  ). 
    Cognitive Abilities at Baseline and Change by the Time of Follow-Up  
  Cognitive functioning tended to decline in the total population and in all subgroups 
during the follow-up period, but the change was statistically significant only in the older age 
group  ( table 3 ).
    Background Data and the Use of CNS Medications 
  Users of CNS medications used more medications overall than did non-users, but the 
demographics between the two groups were similar (  table 4  ).
    Use of a Single Drug with CNS Effects as a Predictor of Cognitive Decline 
 After adjusting for confounding variables (age), the use of BZD or any psychotropic drug 
was still associated with the risk of cognitive decline in older (  6  75 years) patients (  table 5  ). 
    Concomitant Use of Two or More Drugs as a Predictor of Cognitive Decline 
  After adjusting for the confounding variable (age), concomitant use of BZD with AP or 
any drug with CNS effects was still associated with cognitive decline in the total population.
    Concomitant use of BZD and AD or ACh or any drug with CNS effects was associated 
with cognitive decline in the older population. These associations remained statistically sig-
nificant after adjusting for the confounding variable (age).
Table 1.   Single and concomitant use of drugs with CNS effects at baseline, at follow-up examination and 
at both times in a population aged ≥65 years with an MMSE total score of 0–23
Baseline 
(n = 52)
F ollow-up 
(n = 52)
Both at baseline and 
follow-up (n = 52)
n%n % n %
Ops 6 12 6 12 2 4
AChs 12 23 14 27 8 15
APs 6 12 8 15 4 8
ADs 5 10 9 17 4 8
BZDs 11 21 15 29 7 13
AEs 1 2 2 4 1 2
At least one of the above drugs 24 46 29 56 8 1562
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  Discussion 
  To our knowledge, this is the first longitudinal, population-based study describing and 
analyzing associations between concomitant use of drugs with effects on the CNS and the 
long-term risk of cognitive decline among cognitively disabled aged individuals.
    We were able to show the association between use of any psychotropic drug and the risk 
of cognitive decline in a general population with pre-existing cognitive decline. We could 
also replicate the finding that BZD use predicts precipitous cognitive decline in a population 
Combinations of medications n (  total = 52) %
Op and
ACh 2 4
AE 0 0
BZD 1 2
AP 2 4
AD 2 3
Any of the above drugs  4 8
ACh and
AE 0 0
BZD 3 6
AP 4 8
AD 2 3
Any of the above drugs  9 17
AE and
AD 0 0
BZD 0 0
AP 0 0
Any of the above drugs  0 0
BZD and
AP 1 2
AD 3 6
Any of the above drugs  5 10
AP and
AD 2 4
Any of the above drugs  6 12
AD and
Any of the above drugs 5 10
Table 2.   Concomitant use of 
drugs with CNS effects by drug 
combinations in a population 
aged ≥65 years at baseline with 
pre-existing cognitive decline 
(MMSE score 0–23)
Population M  MSE sum score p value*
at basel  ine 
(1990–1991)
during follow-up 
(1998–1999)
Total population 20.085.5 17.988.8 0.129
Men 19.386.3 15.787.5 0.102
Women 20.485.2 18.889.2 0.406
At baseline 65–74 years 21.982.4 22.387.8 0.341
At baseline ≥75 years 18.786.6 14.788.2 0.003
Val  ues denote means 8 SD. * Wilcoxon signed rank test. 
Table 3.   Cognitive functioning 
measured by MMSE at baseline 
and at a 7.6-year follow-up, by 
gender and age63
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with pre-existing cognitive decrements   [12]  . Previous studies have shown that the use of any 
psychotropic drug   [36]   or, specifically, BZD   [37–40]   or BZD used concomitantly with Ops 
  [30]   is associated with cognitive decline in a non-demented aged population.
    In our study, concomitant use of a BZD with an AD, an ACh, an AP or any drug with 
CNS effects predicted cognitive decline. This is in line with the previous finding   [12]   that 
concomitant use of a BZD and an AP is associated with precipitous cognitive decline. Only 
Table 4.   Background data on the use of medications with CNS effects and significance of the differences between 
users of these drugs and non-users at baseline
Background variable Users 
(n = 24)
Non-users 
(  n = 28) 
p value
Age, years 77.886.6 74.487.5 0.114*
Number of all medications 5.483.2 2.182.1 <0.001*
Number of regularly taken medications 4.282.4 1.781.6 <0.001*
Number of medications taken as needed 1.281.4 0.480.7 0.016*
Number of all medications excluding CNS medications 3.982.9 2.182.1 0.021*
Number of regularly taken medications excluding CNS medications 3.182.2 1.781.6 0.017*
Number of medications taken as needed excluding CNS medications 0.881.2 0.480.7 0.262*
Females 5 (21) 10 (36) 0.238**
Marital status
Married 4 (17) 5 (18)
Unmarried or divorced 8 (33) 15 (54) 0.250**
Widowed 12 (50) 8 (29)
Place of living
7 (29)
13 (54)
4 (17)
7 (29)
8 (67)
1 (4)
15 (65)
6 (26)
2 (9)
5 (21)
0 (0)
10 (42)
0 (0)
5 (21)
4 (17)
1 (4)
1 (4)
0 (0)
1 (4)
0 (0)
1 (4)
8 (29)
20 (71)
0 (0)
8 (29)
20 (71)
0 (0)
24 (86)
4 (14)
0 (0)
1 (4)
1 (4)
10 (36)
3 (11)
2 (7)
2 (7)
0 (0)
0 (0)
1 (4)
0 (0)
0 (0)
0 (0)
0.077**
0.870**
0.119**
0.084**
1.000**
0.660**
0.240**
0.227**
0.397**
0.462**
0.462**
1.000**
0.462**
1.000**
0.462**
At home alone 
At home with other person
In institution or nursing home
Education
Less than basic
Basic
More than basic
Ability to walk
Independently
With assistive device
With help of another person
Diagnosed diseases
Depression
Alcohol-related disease
Hypertension
Hypercholesterolemia
Diabetes mellitus (type I or II)
TIA
Cerebral infarct
Cerebral hemorrhage
Cerebral trauma
Malignant tumor or cancer
HIV, lues or borreliosis
Dementia (all types)
Va  lues denote means 8 SD or numbers with percentages in parentheses.
* Mann-Whitney U test. ** 2 test or Fisher’s exact test. TIA = Transient ischemic attack.64
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one study   [12]   has explored the effect of concomitant use of medications having CNS effects 
on cognitive function in a cognitively disabled population. That study, however, had a short 
follow-up period (12 months) and only included patients diagnosed with Alzheimer’s dis-
ease, excluding patient groups with cognitive decline caused by other disorders. Addition-
ally, that study examined only the use of APs, BZDs and cholinergic medications in Alzhei-
mer’s disease.
    It is obvious that the medications in the present study were used to treat the behavioral 
and psychological symptoms connected to declined cognition   [1–8]   in our sample. The im-
portant question is whether the precipitous cognitive decline among those patients receiving 
medications with CNS effects was directly caused by the medications or is the result of a 
more aggressive dementing disorder with more difficult behavioral and psychological symp-
toms of dementia requiring medical treatment. However, in this sample only one participant 
was diagnosed with dementia and the other diagnosed conditions were not themselves cog-
nitively progressive. Thus, it is possible that the change in MMSE scores was directly caused 
by the medications. One placebo-controlled, randomized controlled trial   [13]   supports the 
idea that AP use (in this study quetiapine, an atypical AP with some anticholinergic proper-
ties) increases the risk of hastened cognitive decline among patients with Alzheimer’s dis-
ease, but it did not assess this risk with the concomitant use of other drugs. Another random-
ized controlled trial found a risk of additional cognitive decline when Alzheimer patients 
with behavioral and psychological symptoms of dementia were treated with atypical APs 
(risperidone, quetiapine, olanzapine) compared to placebo  [14] . The association between use 
of an ACh and cognitive decline has been previously shown in longitudinal epidemiologic 
studies among the aged   [25, 41, 42]  , but no such results have been published for a population 
with cognitive decline at baseline. Only tricyclic ADs and conventional APs were used in our 
population in the beginning of the 1990s, and the strong anticholinergic properties of these 
medications, combined with the CNS-depressing GABAergic properties of BZDs may have 
mediated the detected cognitive adverse effects.
    Complete cognitive follow-up data were obtained for 52 participants. The prospective, 
longitudinal design of this study is a major methodological strength. A longitudinal popula-
tion study such as the one we performed cannot directly show causalities, but it shows asso-
ciations between certain factors and the risk of a harmful effect. Many known risk factors 
(excluding the use of alcohol) could be adjusted for in our study.
Table 5.   Significant associations between the use of psychotropics or other drugs with CNS effects and change in cognitive 
functioning (MMSE) during a 7.6-year follow-up, by gender and age
Medication Age Baseline MMSE MMSE at follow-up C  hange in MMSE
users controls p users controls users controls p for 
diff.
adjusted 
p
n mean 8 SD n mean 8 SD mean 8 SD2 mean 8 SD2
BZD1 75+ 8 20.982.8 11 21.183.3 0.729 12.387.6 17.8 85.6 –8.687.0 –3.385.6 0.116 0.015
BZD2 75+ 8 20.982.8 22 17.987.5 0.532 12.387.6 15.688.4 –8.687.0 –2.385.9 0.027 0.002
Any psychotropic drug2 (AP, BZD, AD) 75+ 12 16.988.0 18 19.985.5 0.318 11.088.7 17.287.0 –5.987.0 –2.786.4 0.309 0.037
BZD and
AP1 65+ 1 23 27 21.582.9 0.415 7 20.187.2 –16 –1.487.8 0.137 0.038
AD1 75+ 3 18.783.8 11 21.183.3 0.371 8.081.7 17.885.6 –10.784.7 –3.285.6 0.085 0.021
Any drug with CNS effects1 65+ 5 20.083.3 27 21.582.9 0.329 10.4810.5 20.187.2 –9.689.9 –1.487.8 0.101 0.038
ACh1 75+ 2 18.683.5 11 21.183.3 0.184 3.584.9 17.885.6 –15.088.5 –3.385.6 0.059 0.042
Any drug with CNS effects1 75+ 4 19.383.3 11 21.183.3 0.279 6.084.4 17.885.6 –13.386.5 –3.385.6 0.031 0.003
Any drug with CNS effects2 65+ 5 20.083.3 47 20.085.7 0.603 10.4810.5 18.788.3 –9.689.9 –1.387.2 0.064 0.045
Any drug with CNS effects2 75+ 4 19.383.3 26 18.687.0 0.573 6.084.4 16.087.8 –13.386.5 –2.685.6 0.009 0.001
p   = p value for difference in MMSE at baseline between users and controls; p for diff. = p value for difference of change in MMSE between users and controls; adjusted
p = p value for difference of change in MMSE between users and controls adjusted for confounding variables (age). 1 Control group: no medication with effects on CNS.
2 Control group: non-users of corresponding medications.65
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  Our cohort consists of an older general population with cognitive decline. The participa-
tion rates were high in both phases of the Lieto study. Medication history and clinical back-
ground data were recorded reliably. The measure of cognitive functioning (MMSE, a measure 
of general cognitive performance) is a frequently used, validated instrument for assessing 
global cognitive functioning. Only participants who had a MMSE total score of 0–23, indicat-
ing cognitive decline at baseline, were included in the present study. The MMSE cut-off point 
of 24/23 provides a sensitivity of 69% and a specificity of 99% for dementia   [43]  . Data on cog-
nitive change were available only for individuals who were alive and participated in both 
phases. The difference in the number of subjects between Phase 1 and Phase 2 is accounted 
for by individuals who had died during the follow-up period, refused to participate, or were 
lost to follow-up. We adjusted the results for several known risk factors of cognitive decline, 
but co-existing medical or other conditions or behaviors (e.g. the use of alcohol) may also be 
related to cognitive decline. Alcohol use was not measured during the first phase, therefore 
we could not use it as a confounding variable. However, in our population only one subject 
had a diagnosis of excessive alcohol use. Previous studies on alcohol use among Finns have 
shown that it diminishes with increasing age. A previous study found only a few older indi-
viduals who were classified as frequent users and who drank large quantities of alcohol   [44]  . 
In our study, the majority of participants (13 of 15 men and 35 of 37 women) were living at 
home at baseline. During the follow-up, no men, but 13 of 37 women were institutionalized. 
We suggest that the material did not include current heavy users of alcohol.
    During the early 1990s, it was rare for aged Finns to receive medications with CNS ef-
fects. The concomitant use of several drugs with CNS effects was even rarer. These facts in-
fluence the power of the statistical tests, especially in analyzing the data adjusted for gender 
and age. Drug use categories were determined by the data from the first phase of the study. 
Additional drugs may have been started and previous ones may have been discontinued dur-
ing the follow-up. However, many of these kinds of drugs are prescribed on a long-term basis, 
for many years among the aged in Finland, even against recommendations (e.g. BZD)   [45]  . 
The great majority of medications in the study population were used on a long-term basis.
    No cholinergic medication for Alzheimer’s disease was approved for marketing during 
the study period, and therefore, this category could not be analyzed. Only conventional APs 
were available in the beginning of the 1990s; thus, differences between conventional and 
atypical APs could not be studied either. Tricyclic ADs were the only class of ADs used, 
meaning that no comparison between tricyclic ADs and newer ADs (e.g. SSRI) was possible.
    The number of individuals using two or more medications with CNS effects concomi-
tantly was low. This poses statistical limitations. Negative results may be caused by the rath-
er small sample size and the small number of users. Due to a lack of statistical power, the 
results do not prove that medications with CNS effects have a negative effect on cognition. 
Positive results, especially measured by the quite insensitive MMSE, however, show strong 
associations in this population. Based on the results from the present study, prescribing two 
or more medications with CNS effects to cognitively disabled older individuals should be 
based on a critical, individualized assessment. The cognitively disabled requiring treatment 
with multiple psychotropics should be carefully monitored to permit earlier detection of the 
precipitous cognitive decline associated with the use of these medications.
  Conclusions 
  The use of a BZD or any psychotropic medication may be an independent risk factor for 
further cognitive decline in the cognitively disabled aged. The concomitant use of a BZD and 
an AP, an AD, an ACh or any CNS-affecting medication poses a higher risk of precipitous 66
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